Wary pharma: AstraZeneca sours on UK

From impasse in Iran to still-unresolved conflicts in Gaza and Lebanon, a trend is clear: President Donald Trump’s scant, early plans for peace do not actually forge a path to it. Our correspondent says that in the driverless-car future, it will often be Chinese AI behind the whe ...  Show more

A dive into the data reveals that, despite dire past predictions, the prevalence of dementia is actually waning. We take a look at Pix, a beloved Brazilian digital-payments system, and why it so bothers President Donald Trump. And we attend one of the concerts that reveals how th ...  Show more

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean a ...  Show more

An AstraZeneca vaccine trial on children gets put on pause while a possible link with rare blood clots is investigated. And former Bank of England governor, Mark Carney, talks climate change, fintech and... should Adam sell his Bitcoin? Today’s Newscast was made by Sam Bonham wit ...  Show more

AstraZeneca has drawn up plans to break out its China business, and France is challenging a German-led plan to build up Europe’s air defences. Plus, US businesses are cutting back on their investments in diversity and inclusion. 

Mentioned in this p ...

As a number of existing therapies are being re-purposed to help patients with the most severe Covid-19 symptoms, we speak to a UK-based bioscience company about a drug they've developed and explore how it is being used in Italy. Guests: Tom Whipple, The Times science editorSomeit ...  Show more